1. Academic Validation
  2. Structural bases for the affinity-driven selection of a public TCR against a dominant human cytomegalovirus epitope

Structural bases for the affinity-driven selection of a public TCR against a dominant human cytomegalovirus epitope

  • J Immunol. 2009 Jul 1;183(1):430-7. doi: 10.4049/jimmunol.0900556.
Stéphanie Gras 1 Xavier Saulquin Jean-Baptiste Reiser Emilie Debeaupuis Klara Echasserieau Adrien Kissenpfennig François Legoux Anne Chouquet Madalen Le Gorrec Paul Machillot Bérangère Neveu Nicole Thielens Bernard Malissen Marc Bonneville Dominique Housset
Affiliations

Affiliation

  • 1 Institut de Biologie Structurale Jean-Pierre Ebel, CEA, CNRS, UJF, PSB, Grenoble, France.
Abstract

Protective T cell responses elicited along chronic human CMV (HCMV) infections are sometimes dominated by CD8 T cell clones bearing highly related or identical public TCR in unrelated individuals. To understand the principles that guide emergence of these public T cell responses, we have performed structural, biophysical, and functional analyses of an immunodominant public TCR (RA14) directed against a major HLA-A*0201-restricted HCMV Ag (pp65(495-503)) and selected in vivo from a diverse repertoire after chronic stimulations. Unlike the two immunodominant public TCRs crystallized so far, which focused on one peptide hotspot, the HCMV-specific RA14 TCR interacts with the full array of available peptide residues. The conservation of some peptide-MHC complex-contacting Amino acids by lower-affinity TCRs suggests a shared TCR-peptide-MHC complex docking mode and supports an Ag-driven selection of optimal TCRs. Therefore, the emergence of a public TCR of an oligoclonal Ag-specific response after repeated viral stimulations is based on a receptor displaying a high structural complementarity with the entire peptide and focusing on three peptide hotspots. This highlights key parameters underlying the selection of a protective T cell response against HCMV Infection, which remains a major health issue in patients undergoing bone marrow transplantation.

Figures